Patent Law Weblog
recent posts
- Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
about
Category: Patent Litigation
-
By Donald Zuhn — Earlier this month, we reported that the PricewaterhouseCoopers 2007 Patent and Trademark Damages Study showed that patent actions had dropped more than 11% in 2005. The Intellectual Property Owners Association (IPO) reported today that data released this week from the Administrative Office of the U.S. Courts indicates that after…
-
By Donald Zuhn On Monday, Canadian pharmaceutical company Biovail (NYSE: BVF) announced that it had reached a comprehensive settlement with Anchen Pharmaceuticals, Impax Laboratories, Teva Pharmaceutical Industries, and Watson Pharmaceuticals with respect to Wellbutrin XL® (bupropion HCl), a once-daily antidepressant which has a low incidence of sexual dysfunction, weight gain, and somnolence, and…
-
By Donald Zuhn Last Monday, PricewaterhouseCoopers announced the release of its 2007 Patent and Trademark Damages Study. According to the study, while the number of patent infringement actions increased every year between 1991 and 2004, the number of filed patent cases dropped in 2005 – constituting the first decline in sixteen years. In…
-
By Donald Zuhn Danisco A/S has announced that as a result of a finding of willful infringement by the District Court of Delaware, it would have to pay Novozymes A/S $8.2 million in damages, as well as a share of Novozymes’ legal fees. Patent Docs reported on the Novozymes case last month (Defendant…
-
By Sherri Oslick On February 12, 2007 the House of Representatives passed bill H.R. 34, designed to "encourage enhancement of expertise in patent cases among district judges." The bill establishes a pilot program in certain district courts providing the judges of those districts with the opportunity to decline to hear patent cases. Under the…
-
By Christopher P. Singer In a February 9, 2007 press release, Sanofi-Aventis announced that it has lost its patent infringement suit against generic drugmakers Amphastar Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd., filed in the U.S. District Court for the Central District of California. The suit relates to Sanofi-Aventis’ blockbuster blood thinning drug,…
-
By Donald Zuhn — On January 22, 2007, the Federal Circuit announced a proposal to amend its rules by adopting Federal Circuit Rules 28(a)(15) and (16), 28(j), 30(k), and 31(b), (e), and (f); and by deleting Federal Circuit Rule 32(e). According to the Court's announcement, the rule changes would require parties represented by…
-
By Mark Chael — On Thursday, January 11, 2007, Digene filed suit against Third Wave Technologies, Inc. in the U.S. District Court for the Western District of Wisconsin (Case No. 07-C-0022-C) alleging infringement of U.S. Patent No. 5,643,715 (the '715 patent), in the latest skirmish of the ongoing battle between these two companies…
-
By Donald Zuhn — In response to the adoption of Federal Rule of Appellate Procedure 32.1, the Federal Circuit has adopted new Federal Circuit Rule 32.1. Under the new Rule, parties will no longer be prohibited or restricted from citing nonprecedential dispositions issued by the Federal Circuit after January 1, 2007. The new Rule…
-
By Christopher P. Singer — Pfizer and Teva on November 21, 2006 announced that the companies reached an agreement that resolves litigation surrounding the drugs idarubicin and azithromycin, as well as issues relating to epirubicin. The resolution includes full releases between the parties and directs a payment as large as $70 million from…
Patent Docs 